European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy


Janbernd Kirschner, Nina Butoianu, Nathalie Goemans, Jana Haberlova, Anna Kostera-Pruszczyk, Eugenio Mercuri, W. Ludovan der Pol, Susana Quijano-Roy, Thomas Sejersen, Eduardo F.Tizzano, Andreas Ziegler, Laurent Servais, Francesco Muntonio

Spinal muscular atrophy (SMA) used to be one of the most common genetic causes of infant mortality. New disease modifying treatments have changed the disease trajectories and most impressive results are seen if treatment is initiated in the presymptomatic phase of the disease. Very recently, the European Medicine Agency approved Onasemnogene abeparvovec (Zolgensma®) for the treatment of patients with SMA with up to three copies of the SMN2 gene or the clinical presentation of SMA type 1. While this broad indication provides new opportunities, it also triggers discussions on the appropriate selection of patients in the context of limited available evidence. To aid the rational use of Onasemnogene abeparvovec for the treatment of SMA, a group of European neuromuscular experts presents in this paper eleven consensus statements covering qualification, patient selection, safety considerations and long-term monitoring.

Published: 9 July 2020
Journal: European Journal of Paediatric Neurology


The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit